产前糖皮质激素对早期足月剖宫产母儿的影响:一项多中心随机对照研究

注册号:

Registration number:

ChiCTR2300074647 

最近更新日期:

Date of Last Refreshed on:

2023-12-26 19:43:07 

注册时间:

Date of Registration:

2023-08-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

产前糖皮质激素对早期足月剖宫产母儿的影响:一项多中心随机对照研究

Public title:

Antenatal corticosteroids prior to early term elective caesarean section: a multi-center, randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

产前糖皮质激素对早期足月剖宫产母儿的近远期影响:一项多中心随机对照研究

Scientific title:

Antenatal corticosteroids prior to early term elective caesarean section (from 37+0 to 38+6 weeks gestation): a multi-center, randomized controlled trial assessing the effects on maternal and neonatal short- and long-term outcomes

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

白雪琪 

研究负责人:

石中华 

Applicant:

Xueqi Bai 

Study leader:

Zhonghua Shi 

申请注册联系人电话:

Applicant telephone:

+86 150 0520 1810

研究负责人电话:

Study leader's
telephone:

+86 138 5181 2725

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bainjmu@163.com

研究负责人电子邮件:

Study leader's E-mail:

jesse_1982@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市莫愁路天妃巷123号

研究负责人通讯地址:

江苏省南京市莫愁路天妃巷123号

Applicant address:

123, Tianfeixiang, Mochou Road, Nanjing, Jiangsu

Study leader's address:

123, Tianfeixiang, Mochou Road, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学附属妇产医院(南京市妇幼保健院)

Applicant's institution:

Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal

研究负责人所在单位:

南京医科大学附属妇产医院(南京市妇幼保健院)

Affiliation of the Leader:

Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022KY-166-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京市妇幼保健院(南京医科大学附属妇产医院)医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Nanjing Maternity and Child Health Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-10 00:00:00

伦理委员会联系人:

高芯

Contact Name of the ethic committee:

Xin Gao

伦理委员会联系地址:

江苏省南京市莫愁路天妃巷123号

Contact Address of the ethic committee:

123, Tianfeixiang, Mochou Road, Nanjing, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 5222 6919

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学附属妇产医院(南京市妇幼保健院)

Primary sponsor:

Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal

研究实施负责(组长)单位地址:

江苏省南京市莫愁路天妃巷123号

Primary sponsor's address:

123, Tianfeixiang, Mochou Road, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学附属妇产医院(南京市妇幼保健院)

具体地址:

江苏省南京市莫愁路天妃巷123号

Institution
hospital:

Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal

Address:

123, Tianfeixiang, Mochou Road, Nanjing, Jiangsu

经费或物资来源:

国家重点研发计划子课题(2022YFC2703503)

Source(s) of funding:

National key research and development program(2022YFC2703503)

研究疾病:

早期足月分娩  

Target disease:

early term labor

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

III期临床试验 

Study phase:

3

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨产前糖皮质激素治疗对37~38+6周足月择期剖宫产母儿的近远期影响。  

Objectives of Study:

To estimate the effects of antenatal corticosteroids on maternal and neonatal short- and long-term outcomes

药物成份或治疗方案详述:

试验组:剖宫产术前7日内给予1个疗程地塞米松磷酸钠注射液6mg肌内注射,每12小时1次,共4次。 对照组:不给予干预。 

Description for medicine or protocol of treatment in detail:

Intervention group: 4 doses of 6 mg dexamethasone sodium phosphate by intramuscular injection into the buttock, 12 hours apart given within seven days of elective caesarean section. Control group: no intervention. 

纳入标准:

Inclusion criteria

排除标准:

1.对本药或其他肾上腺皮质激素类药物过敏或不耐受者; 2.妊娠合并症或并发症:特发性血小板减少性紫癜、血栓症; 3.全身或局部严重感染; 4.严重心、肝、肾功能不全; 5.有精神疾病史或癫痫病史; 6.胎儿合并先天畸形及遗传代谢性疾病; 7.研究者判定可能干扰试验结果或增加患者风险的病史或用药禁忌; 8.本次妊娠已接受糖皮质激素药物治疗; 9.本次妊娠参加其他药物临床研究。

Exclusion criteria:

1. Intolerant to dexamethasone or other adrenal corticosteroids; 2. Pregnancy complications: idiopathic thrombocytopenic purpura, thrombosis; 3. Severe infection; 4. Severe heart, liver and renal diseases; 5. Mental illness or epilepsy; 6. Fetal demise, or known major fetal anomaly; 7. Medical history or medication contraindications that may interfere with the test results or increase the patient's risk; 8. Any prior antenatal corticosteroid course during the pregnancy; 9. Participation in another interventional study during the pregnancy.

研究实施时间:

Study execute time:

From 2023-09-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-01 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

750

Group:

Intervention group

Sample size:

干预措施:

剖宫产术前7日内给予1个疗程地塞米松磷酸钠注射液6mg肌内注射,每12小时1次,共4次。

干预措施代码:

Intervention:

4 doses of 6 mg dexamethasone sodium phosphate by intramuscular injection into the buttock, 12 hours apart given within seven days of elective caesarean section

Intervention code:

组别:

对照组

样本量:

750

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学附属妇产医院(南京市妇幼保健院) 

单位级别:

三甲 

Institution
hospital:

Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hostipal

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

常州市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Changzhou Maternal and Child Health Care Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

常州市第二人民医院 

单位级别:

三甲 

Institution
hospital:

Changzhou NO.2 People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

苏州市立医院 

单位级别:

三甲 

Institution
hospital:

Suzhou Municipal Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

无锡市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Wuxi Maternal and Child Health Care Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

新生儿呼吸窘迫综合征

指标类型:

主要指标

Outcome:

neonatal respiratory distress syndrome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿暂时性呼吸增快症

指标类型:

主要指标

Outcome:

neonatal temporary hyperrespiratory syndrome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿窒息

指标类型:

主要指标

Outcome:

neonatal asphyxia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新生儿低血糖症

指标类型:

主要指标

Outcome:

neonatal hypoglycemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸支持率

指标类型:

主要指标

Outcome:

rate of respiratory support

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NICU住院率

指标类型:

次要指标

Outcome:

NICU admission rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NICU住院时间

指标类型:

次要指标

Outcome:

length of NICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

孕产妇发热

指标类型:

次要指标

Outcome:

maternal fever

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

绒毛膜羊膜炎

指标类型:

次要指标

Outcome:

chorioamnionitis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产褥感染

指标类型:

次要指标

Outcome:

puerperal infection

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Faeces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

羊水

组织:

Sample Name:

Amniotic fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

组长单位使用计算机随机数字生成程序进行简单随机化分配,将符合条件且签署知情同意书的受试者按1:1的比例随机分配到试验组和治疗组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization will be stratified by study center, with allocation ratio of 1:1 for each group. A random list of numbers will be generated using computer.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后与研究者联系,经过研究者同意后共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

At the end of the trial, data will be accessible with the investigator's consent.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-11 11:26:57